104 research outputs found

    Adding Diversity to a Diruthenium Biscyclopentadienyl Scaffold via Alkyne Incorporation: Synthesis and Biological Studies

    Get PDF
    We report the synthesis and the assessment of the anticancer potential of two series of diruthenium biscyclopentadienyl carbonyl complexes. Novel dimetallacyclopentenone compounds (2-4) were obtained (45-92% yields) from the thermal reaction(PhCCPh exchange) of [Ru2Cp2(CO)(& mu;-CO){& mu;-& eta;(1):& eta;(3)-C(Ph)C(Ph)C(O)}], 1, with alkynes HCCR [R = C5H4FeCp (Fc),3-C6H4(Asp), 2-naphthyl; Cp = & eta;(5)-C5H5, Asp = OC(O)-2-C6H4C(O)Me]. Protonation of 1-3 by HBF4 afforded the corresponding & mu;-alkenyl derivatives 5-7, in 40-86% yields. All productswere characterized by IR and NMR spectroscopy; moreover, cyclic voltammetry(1, 2, 5, 7) andsingle-crystal X-ray diffraction (5, 7)analyses were performed on representative compounds. Complexes 5-7 revealed a cytotoxic activity comparableto that of cisplatin in A549 (lung adenocarcinoma), SW480 (colon adenocarcinoma),and ovarian (A2780) cancer cell lines, and 2, 5, 6, and 7 overcame cisplatin resistancein A2780cis cells. Complexes 2, 5, and 7 (but not the aspirin derivative 6) inducedan increase in intracellular ROS levels. Otherwise, 6 strongly stabilizes and elongates natural DNA (from calf thymus,CT-DNA), suggesting a possible intercalation binding mode, whereas 5 is less effective in binding CT-DNA, and 7 isineffective. This trend is reversed concerning RNA, and in particular, 7 is able to bind poly(rA)poly(rU) showing selectivity forthis nucleic acid. Complexes 5-7 caninteract with the albumin protein with a thermodynamic signature dominatedby hydrophobic interactions. Overall, we show that organometallicspecies based on the Ru2Cp2(CO)( x ) scaffold (x = 2, 3) are activeagainst cancer cells, with different incorporated fragments influencingthe interactions with nucleic acids and the production of ROS

    When ferrocene and diiron organometallics meet: triiron vinyliminium complexes exhibit strong cytotoxicity and cancer cell selectivity

    Get PDF
    Cationic triiron complexes resulting from the conjugation of the ferrocenyl skeleton (Fc) with a diiron bis-cyclopentadienyl core through a variable vinyliminium linker, [Fe2Cp2(CO)(mu-CO){mu-eta(1):eta(3)-C(Fc)CHCN(R)(R')}]CF3SO3 ([2a-i]CF3SO3, Cp = eta(5)-C5H5, R, R'= alkyl, aryl), were synthesised in 70-94% yield, and the homologous nitrate salt was also prepared in one case ([2h]NO3). The neutral derivatives [Fe2Cp2(CO)(mu-CO){mu-eta(1):eta(3)-C(Fc)CHC(CN)NMe2}], 3, and [FeCp(CO){CN(Me)(Xyl)CHC(Fc)C(=O)}], 4 (Xyl = 2,6-C6H3Me2), were obtained in ca. 70% yield by reactions of the respective precursors [2h]CF3SO3 and [2i]CF3SO3 with NBu4CN and pyrrolidine, respectively. All products were purified by alumina chromatography and fully characterised by analytical and spectroscopic methods, and by single crystal X-ray diffraction in the cases of [2a]CF3SO3 and 3. The cytotoxicity of the complexes was assessed on A2780, A2780cisR and BxPC-3 cancer cell lines, and the nontumoral Balb/3T3 clone A31. Most of the cationic complexes display IC50 values in the low micromolar/nanomolar range concerning the cancer cell lines, and up to 35 times higher values on the nontumoral cells. In order to shed light on the mode of action, selected complexes were further characterised by cyclic voltammetry and spectroelectrochemical experiments, and assessed for their potential to trigger ROS production and to interact with a range of biomolecules, i.e. a synthetic dodecapeptide as a simplified model for thioredoxin reductase (TrxR-pept), some model proteins (cytochrome c, hen egg-white lysozyme, ubiquitin, bovine serum albumin, superoxide dismutase and human carbonic anhydrase) and one single-stranded oligonucleotide (ODN2)

    An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study

    Get PDF
    Background: The treatment of patients with brain-spread renal cell carcinoma (RCC) is an unmet clinical need, although more recent therapeutic strategies have significantly improved RCC patients' life expectancy. Our multicenter, retrospective, observational study investigated a real-world cohort of patients with brain metastases (BM) from RCC (BMRCC). Patients and methods: A total of 226 patients with histological diagnosis of RCC and radiological evidence of BM from 22 Italian institutions were enrolled. Univariate and multivariate models were performed to investigate the impact of clinicopathological features and multimodal treatments on both overall survival (OS) from the BM diagnosis and intracranial progression-free survival (iPFS). Results: The median OS from the BM diagnosis was 18.8 months (interquartile range: 6.2-43 months). Multivariate analysis confirmed the following as positive independent prognostic factors: a Karnofsky Performance Status >70% [hazard ratio (HR) = 0.49, 95% confidence interval (CI) 0.26-0.92, P = 0.0026] and a single BM (HR = 0.51, 95% CI 0.31-0.86, P = 0. 0310); in contrast, the following were confirmed as worse prognosis factors: progressive extracranial disease (HR = 1.66, 95% CI 1.003-2.74, P = 0.00181) and only one line of systemic therapy after the BM occurrence (HR = 2.98, 95% CI 1.62-5.49, P = 0.029). Subgroup analyses showed no difference in iPFS according to the type of the first systemic treatment [immunotherapy (IT) or targeted therapy (TT)] carried out after the BM diagnosis (HR = 1.033, 95% CI 0.565-1.889, P = 0.16), and revealed that external radiation therapy (eRT) significantly prolonged iPFS when combined with IT (10.7 months, 95% CI 4.9-48 months, P = 0.0321) and not when combined with TT (9.01 months, 95% CI 2.7-21.2 months, P = 0.59). Conclusions: Our results suggest a potential additive effect in terms of iPFS for eRT combined with IT and encourage a more intensive multimodal therapeutic strategy in a multidisciplinary context to improve the survival of BMRCC patients

    Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma

    Get PDF
    Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several clinicopathologic parameters and survival. Overall, fascin immunoreactivity was detected in 162 (71%) tumours with a prevalence for right-sided tumours (P<0.001). Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases. Patients with fascin-expressing tumours experienced a shorter disease-free and overall survival in comparison with those with negative tumours, and fascin immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. Moreover, patients with the same tumour stages could be stratified in different risk categories for relapse and progression according to fascin expression. Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas

    Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience

    Get PDF
    BACKGROUND: Patients with metastatic colorectal cancer (mCRC) refractory to standard therapies have a poor prognosis. In this setting, recruitment into clinical trials is warranted, and studies driven by selection according to individual tumor molecular characteristics are expected to provide added value. OBJECTIVE: We retrospectively analyzed data from patients with mCRC refractory to or following failure of standard therapies who were enrolled into phase I/II clinical studies at the Niguarda Cancer Center based on the presence of a specific molecular profile expected to represent the target of susceptibility to the experimental drug(s). PATIENTS AND METHODS: From June 2011 to May 2016, 2044 patients with mCRC underwent molecular screening. Eighty patients (3.9%) were enrolled in ad hoc studies; the median age was 60 years (range 36-86) and the median number of previous treatment lines was five (range 2-8). Molecular characteristics exploited within these studies were MGMT promoter hypermethylation (48.7%), HER2 amplification (28.8%), BRAF V600E mutation (20%), and novel gene fusions involving ALK or NTRK (2.5%). RESULTS: One patient (1%) had RECIST (Response Evaluation Criteria In Solid Tumors) complete response (CR), 13 patients (16.5%) experienced a partial response (PR), and 28 (35%) stable disease (SD). Median progression-free survival (PFS) was 2.8 months (range 2.63-3.83), with 24% of patients displaying PFS >5 months. Median growth modulation index (GMI) was 0.85 (range 0-15.61) and 32.5% of patients had GMI >1.33. KRAS exon 2 mutations were found in 38.5% of patients, and among the 78 patients with known KRAS status, those with wild-type tumors had longer PFS than those with mutated tumors (3.80 [95% CI 2.80-5.03] vs. 2.13 months [95% CI 1.77-2.87], respectively, p = 0.001). Median overall survival (OS) was 7.83 months (range 7.17-9.33) for all patients, and patients with KRAS wild-type tumors had longer OS than those with mutated tumors (7.83 [95% CI 7.33-10.80] vs. 7.18 months [95% CI 5.63-9.33], respectively, p = 0.06). CONCLUSIONS: This single-institution retrospective study indicates that in a heavily pretreated population approximately 4% of mCRC tumors display a potential actionable molecular context suitable for therapeutic intervention. Application of molecular selection is challenging but improves clinical outcome even in later lines of treatment

    Procedimento di riduzione del complesso Pd(NH3)2Cl2 a spugna di palladio

    No full text
    La presente invenzione rigurda un procedimento di riduzione del complesso Pd(NH3)2Cl2 a spugna di palladio che prevede i seguenti passaggi : a) dissoluzione del complesso Pd(NH3)2Cl2 in soluzione acquosa in eccesso di ammoniaca; b) aggiunta di acido cloridrico in quantità tale da ottenere un valore di pH compreso nell'intervallo da 6 a 9; c) riduzione con acido formico ad una temperatura compresa tra 60 e 100°C; e e) eliminazione di cloruro di amminio e/o di carbonato di ammonio eventualmente presenti nella spugna proveniente dal passaggio c). La spugna di palladio così ottenuta, è estremamente pura e ha un'eccellente granulometria

    Mutual Catalysis of Neutral and Anionic Cobalt Carbonyls in Their CO Scrambling Reactions

    No full text
    Redox-condensation equilibria, probably with the participation of [Co3(CO)10]- as intermediate, and not ion pairing as previously postulated, explain the acceleration of the CO scrambling in [Co(CO)4]- by alkali metal counterions. The studies described here show that neutral carbonyl complexes catalyze the CO scrambling for anionic metal carbonyls and vice versa, and that the catalysis is less effective in the presence of free CO. The latter is in agreement with [Co3(CO)10]- as the intermediate. These results are important mainly because neutral and anionic metal carbonyls frequently exist together as a result of side reactions

    Reduction of Methanol by Tetracarbonylcobalt Anion Assisted by Carbon Dioxide and Cobalt Cation

    No full text
    Fundamental electron-transfer reactions involving CH3OH and Co2(CO)8 are investigated. In a fully disproportionated CH3OH solution of Co2(CO)8, in the presence of CO2, a CH3OH reduction by Co(CO)4- occurs, under the intervention of the highly polarizing Co2+ cations. In tetrahydrofuran as solvent under carbon monoxide atmosphere, the CH3O- nucleophile formed gives rise to the Co(I) species tetracarbonyl(methoxycarbonyl)cobalt. Under low carbon monoxide pressure, this Co(I) species disproportionates to Co(OCH3)2 and Co2(CO)8. Catalytic amounts of Co2(CO)8 activate the carbonylation reaction of Co(OCH3)2 to dimethyl carbonate and tetracarbonyl(methoxycarbonyl)cobalt

    Preparation of Dimethyl Carbonate by Dehydrogenative Carbonylation

    No full text
    A new dimethylcarbonate synthesis method by means of a dehydrogenatingcarbonylation method which only uses methanol, CO, CO2 and CO2(CO)8. Newintermediate products used to carry out said method
    • …
    corecore